Haemonetics Corporation (HAE)
| Market Cap | 5.47B +125.9% |
| Revenue (ttm) | 1.38B +4.1% |
| Net Income | 103.91M -38.2% |
| EPS | 2.24 -34.8% |
| Shares Out | 45.50M |
| PE Ratio | 53.69 |
| Forward PE | 21.14 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 418,446 |
| Open | 121.16 |
| Previous Close | 124.11 |
| Day's Range | 116.79 - 123.75 |
| 52-Week Range | 51.00 - 132.00 |
| Beta | 0.59 |
| Analysts | Buy |
| Price Target | 124.50 (+3.55%) |
| Earnings Date | Nov 5, 2026 |
About HAE
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management syst... [Read more]
Financial Performance
In fiscal year 2026, Haemonetics's revenue was $1.33 billion, a decrease of -1.97% compared to the previous year's $1.36 billion. Earnings were $97.31 million, a decrease of -41.97%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for HAE stock is "Buy." The 12-month stock price target is $124.5, which is an increase of 3.55% from the latest price.
News
Haemonetics participates in a conference call with JPMorgan
Medical Supplies & Devices Allen Gong, along with Vice President Olga Guyette hold a post F2Q conference call on November 6 at 12:30 pjm. Webcast Link
Haemonetics price target raised to $145 from $140 at Barrington
Barrington analyst Michael Petusky raised the firm’s price target on Haemonetics (HAE) to $145 from $140 and keeps an Outperform rating on the shares. The CSL rollout has already started…
Haemonetics price target raised to $165 from $140 at Mizuho
Mizuho analyst Anthony Petrone raised the firm’s price target on Haemonetics (HAE) to $165 from $140 and keeps an Outperform rating on the shares.
Haemonetics price target raised to $149 from $123 at Citi
Citi raised the firm’s price target on Haemonetics (HAE) to $149 from $123 and keeps a Buy rating on the shares.
Haemonetics price target raised to $165 from $142 at Baird
Baird raised the firm’s price target on Haemonetics (HAE) to $165 from $142 and keeps an Outperform rating on the shares. The firm updated its model moving numbers meaningfully higher…
Haemonetics management to meet with Barrington
Meeting to be held in Denver on November 12 hosted by Barrington.
Haemonetics Earnings Call Transcript: Q2 2027
Organic revenue grew 10% in Q2 and 8% in H1, with adjusted EPS up 6% in both periods. FY27 revenue guidance rose, while operating-margin expansion guidance narrowed as capacity investments and cost pressures weigh on the near term.
Haemonetics Earnings release: Q2 2027
Haemonetics released its Q2 2027 earnings on November 5, 2026, summarizing the period's financial results.
Haemonetics Quarterly report: Q2 2027
Haemonetics has published its Q2 2027 quarterly earnings report on November 5, 2026.
Haemonetics Slides: Q2 2027
Haemonetics has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on November 5, 2026.
Haemonetics reports Q2 adjusted EPS $1.35, consensus $1.29
Reports Q2 revenue $357.76M, consensus $345.15M. Chris Simon, Haemonetics (HAE)’ CEO, stated: “Our second-quarter and first-half results reflect significant momentum across our businesses. Expansion o...
Haemonetics raises FY26 adjusted EPS view to up 8%-11% from up 5%-8%
Raises FY26 revenue view to up 8%-11% from up 5%-8%.
Haemonetics Corporation Announces Second Quarter Fiscal 2027 Financial Results Available on Investor Relations Website
Financial release and supplemental presentation accessible online BOSTON, Nov. 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fisca...
Haemonetics says FDA approves PerQseal Elite vascular closure system
Haemonetics (HAE) announced U.S. FDA approval of the PerQseal Elite vascular closure system for large-bore arterial procedures. The approval expands Haemonetics’ portfolio of clinically-differentiated...
Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure System
BOSTON, Oct. 19, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today an...
Haemonetics price target raised to $140 from $95 at Mizuho
Mizuho analyst Anthony Petrone raised the firm’s price target on Haemonetics (HAE) to $140 from $95 and keeps an Outperform rating on the shares after the company updated its previously…
Haemonetics price target raised to $140 from $118 at Barrington
Barrington raised the firm’s price target on Haemonetics (HAE) to $140 from $118 and keeps an Outperform rating on the shares. The firm updated the company’s model to reflect its…
Haemonetics price target raised to $140 from $120 at BofA
BofA raised the firm’s price target on Haemonetics (HAE) to $140 from $120 and keeps a Buy rating on the shares after CSL announced that it will transition away from…
Why Is Haemonetics Stock (HAE) Up Over 13% Today?
Haemonetics stock gained after the company released a new SEC filing covering a supply agreement with CSL Plasma.
Haemonetics Stock Surges as Plasma Deal Opens Door to More Revenue
CSL Plasma plans to use Haemonetics' plasma collection equipment across all existing U.S. centers, expanding the scope of an earlier supply agreement.
Haemonetics price target raised to $130 from $110 at BTIG
BTIG raised the firm’s price target on Haemonetics (HAE) to $130 from $110 and keeps a Buy rating on the shares after CSL confirmed it anticipates transitioning to the company’s…
Morning Movers: Haemonetics up sharply after CSL Plasma supply pact
Stock futures are lower as a renewed jump in oil prices and Treasury yields revives inflation concerns. Brent crude jumped nearly 5% to above $105 a barrel, while WTI climbed…
Haemonetics enters non-exclusive supply agreement with CSL Plasma
In a regulatory filing, Haemonetics (HAE) disclosed its entry into a non-exclusive supply agreement with CSL Plasma, under which CSL may utilize the company’s NexSys PCS devices with Persona PLUS…